PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease

Nature Reviews Rheumatology · Published 2025-12-02 · DOI 10.1038/s41584-025-01296-9

Authors being retrieved — see the publisher record. https://doi.org/10.1038/s41584-025-01296-9

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• PD-1 agonism puts the brakes on pathogenic T cell responses in RA · Nature Reviews Rheumatology · 2026 · Cites or is cited by this article · Same journal
• Defining nature, responses and drivers of regulatory- and conventional CD4+ T cells in the human term decidua · Frontiers in Immunology · 2026 · Cites or is cited by this article
• Brepocitinib shows promise for dermatomyositis · Nature Reviews Rheumatology · 2026 · Same journal
• The gut–joint axis in osteoarthritis · Nature Reviews Rheumatology · 2026 · Same journal
• Anti-CD19 CAR T cell therapy promotes skin remodelling in systemic sclerosis · Nature Reviews Rheumatology · 2026 · Same journal
• Progress made and the road ahead for cancer screening in myositis · Nature Reviews Rheumatology · 2026 · Same journal
• 20 years of progress in the classification of immune-mediated diseases · Nature Reviews Rheumatology · 2026 · Same journal
• The evolving comorbidity landscape of rheumatoid arthritis · Nature Reviews Rheumatology · 2026 · Same journal
• Decoding variants of uncertain significance in systemic autoinflammatory diseases · Nature Reviews Rheumatology · 2026 · Same journal
• Sex-dependent mechanisms in rheumatic diseases · Nature Reviews Rheumatology · 2026 · Same journal